Stockscreener 앱 받기
117.42
3.01%
3.43
시간 외 거래:
117.59
0.17
+0.14%
전일 마감가:
$113.99
열려 있는:
$115.26
하루 거래량:
110.53K
Relative Volume:
0.38
시가총액:
$1.68B
수익:
$1.30M
순이익/손실:
$-49.30M
주가수익비율:
-28.17
EPS:
-4.1688
순현금흐름:
$-25.01M
1주 성능:
+7.53%
1개월 성능:
-4.99%
6개월 성능:
+17.43%
1년 성능:
+395.03%
1일 변동 폭
$114.05
$117.61
1주일 범위
$109.10
$117.61
52주 변동 폭
$20.20
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
117.21 | 1.63B | 1.30M | -49.30M | -25.01M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Kathleen Goin, Palvella COO, sells $475,630 in company stock By Investing.com - Investing.com Australia
Kathleen Goin, Palvella COO, sells $475,630 in company stock - Investing.com
Number of shareholders of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards - Sahm
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Palvella Therapeutics Q1 earnings call highlights - MSN
Palvella presents clinical data on topical rapamycin gel By Investing.com - Investing.com Nigeria
Palvella Reports Positive Phase 3 Data for QTORIN - TipRanks
Palvella presents clinical data on topical rapamycin gel - Investing.com
Palvella's QTORIN™ rapamycin shows strong Phase... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Palvella Therapeutics Reports Positive Phase 3 SELVA and Phase 2 TOIVA Study Results for QTORIN™ Rapamycin in Treating Microcystic Lymphatic Malformations and Cutaneous Venous Malformations - Quiver Quantitative
Rare vascular disease trial: 100% of children improved - Stock Titan
Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation - Yahoo Finance
Palvella Eyes 2027 Launch After Positive Phase 3 Results - MyChesCo
Palvella Therapeutics Reports Positive Phase 2 TOIVA Trial Results for QTORIN Rapamycin in Cutaneous Venous Malformations at SID 2026 - Minichart
Palvella presents Phase 2 data on bleeding reduction treatment - Investing.com UK
Palvella presents Phase 2 data on bleeding reduction treatment By Investing.com - Investing.com South Africa
Palvella Unveils Promising Phase 2 Data for QTORIN - TipRanks
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology - The Manila Times
Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations - TradingView
Palvella presents positive Phase 2 TOIVA data showing significant bleeding reduction with QTORIN rapamycin - TradingView
New skin trial eases bleeding in rare disease affecting over 75,000 in U.S. - Stock Titan
Palvella targets 2H 2026 NDA filing while outlining >$1B peak US sales potential for QTORIN rapamycin in microcystic lymphatic malformations - MSN
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market - Sahm
Palvella Therapeutics approved for transfer to Nasdaq Global Market - MSN
Palvella Therapeutics moves to Nasdaq Global Market By Investing.com - Investing.com India
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market - Moomoo
Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Stock Information (NASDAQ: PVLA) 161851 - Minichart
Palvella Therapeutics announces uplisting to the Nasdaq Global Market - marketscreener.com
Palvella Therapeutics to transfer listing to Nasdaq Global Market By Investing.com - Investing.com India
Palvella Therapeutics to transfer listing to Nasdaq Global Market - Investing.com
Palvella Therapeutics moves to Nasdaq Global Market - Investing.com
Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market - TradingView
Palvella Therapeutics, Inc. Primary Exchange Listing will Change to Nasdaq Global Market from Nasdaq Capital Market - marketscreener.com
Palvella Therapeutics | 8-K: Current report - Moomoo
Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN
Stephens initiates Palvella stock with overweight rating, $220 target By Investing.com - Investing.com Canada
Stephens & Co. initiates coverage of Palvella Therapeutics (PVLA) with overweight recommendation - MSN
Palvella Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Mizuho Trims Price Target on Palvella Therapeutics to $240 From $250, Keeps Outperform Rating - Moomoo
Palvella Therapeutics Doses First Patients in Phase 2 Trial for Rare Skin Disease - Moomoo
Palvella Therapeutics Inc (PVLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.49%
0.12%
자본화:
|
볼륨(24시간):